FibroScan for Heart Failure
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests FibroScan, a non-invasive tool, to determine if it can safely and accurately assess heart failure without requiring risky procedures like cardiac catheterization, which examines the heart's blood vessels. It targets individuals who have been diagnosed with or are suspected of having heart failure and are scheduled for a right-sided cardiac catheterization. This trial may suit those experiencing heart failure symptoms and whose doctor has scheduled an invasive heart test. As an unphased study, it offers an opportunity to contribute to research that could make heart failure assessments safer and less invasive for future patients.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this device is safe for heart failure patients?
Research has shown that FibroScan is a safe tool for assessing liver stiffness. It has been used safely in individuals with heart problems without causing major issues. However, caution is advised for those with devices like pacemakers or defibrillators, as some studies suggest it might not be suitable.
For most people, FibroScan is easy to handle and avoids the risks associated with more invasive methods. Being non-invasive, it doesn't involve surgery, reducing the chance of complications. Always consult a doctor to determine if it's the right option.12345Why are researchers excited about this trial?
FibroScan is unique because it offers a non-invasive way to assess heart failure by measuring liver stiffness, which is linked to heart health. Unlike traditional methods that rely on symptom management and imaging techniques, FibroScan uses ultrasound technology to provide real-time insights into liver condition, potentially reflecting heart function. Researchers are excited about this method because it could lead to earlier detection and more personalized treatment strategies for heart failure patients, improving outcomes and reducing the need for more invasive procedures.
What evidence suggests that FibroScan is effective for heart failure?
Studies have shown that FibroScan, a non-invasive tool, effectively measures liver stiffness. This is important because heart failure often affects liver function. One study found that measuring liver stiffness can help predict heart failure outcomes, with higher stiffness linked to worse results. Another study showed that patients with higher stiffness faced a much higher risk of serious health issues. These findings suggest that FibroScan, which participants in this trial will use, might help assess heart failure risk, offering a safer option compared to invasive procedures.46789
Are You a Good Fit for This Trial?
This trial is for individuals with various types of heart failure who are seeking a non-invasive method to assess their heart's function. Participants should be eligible for the standard invasive procedures, but looking for safer alternatives.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Baseline measurements of liver stiffness and echocardiographic parameters are taken
Evaluation
Participants undergo liver stiffness measurement using FibroScan to evaluate elevated CVP
Follow-up
Participants are monitored for any adverse events and the correlation of LSM with clinical parameters
What Are the Treatments Tested in This Trial?
Interventions
- FibroScan
Find a Clinic Near You
Who Is Running the Clinical Trial?
Echosens
Lead Sponsor
Syneos Health
Collaborator